Vincent Lo Re of the University of
Pennsylvania.
Image ©Liz Highleyman / hivandhepatitis.com
|
Researchers in the US compared rates of liver disease and liver-related death between co-infected and hepatitis C-monoinfected people.
Importantly, the co-infected participants were on HIV treatment, which has previously been shown to slow the progression of liver disease.
Co-infected people were at approximately twice the risk of developing decompensated liver disease and 69% more likely to progress
to liver cancer.
An undetectable HIV viral load reduced the risk of liver disease, but even
with HIV suppression outcomes were still poorer in co-infected people compared
to those who only had hepatitis C.
No comments:
Post a Comment